LX31 Stock Chart & Stats
€1.01
€0.00(0.00%)
At close: 4:00 PM EDT
€1.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.95 - €1.45
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€788.32M
Enterprise Value€919.00
Total Cash (Recent Filing)€190.61M
Total Debt (Recent Filing)€59.28M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Nov 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding444,955,930
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.38Price Target Upside334.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€32.82M
Bulls Say, Bears Say
Bulls Say
Deleveraged Balance SheetZero TTM debt and higher equity reduce financial risk and give Lexicon greater flexibility to fund clinical development and commercialization. This stronger balance-sheet position can help sustain investment through upcoming milestones while limiting reliance on immediate refinancing or additional capital.
Late-stage Clinical ProgressCompletion and significant over-enrollment of the SONATA-HCM Phase III study strengthen the evidence base for a potentially important late-stage asset. Greater enrollment may improve study power, supporting a clearer regulatory and commercial path if the primary endpoint is achieved.
Partnered Milestone PotentialThe LX9851 partnership has already produced $20 million in milestone payments and retains additional near-term milestone potential. This validates external interest in the program, diversifies Lexicon’s funding sources, and could support development without relying solely on product sales.
Bears Say
Persistent Cash BurnContinued negative operating and free cash flow shows that Lexicon’s operations are not yet self-funding. Even with improved liquidity, ongoing cash consumption can require external financing or partnership proceeds, potentially limiting strategic flexibility if profitability does not improve.
Volatile And Limited Revenue BaseRevenue remains volatile and the current commercial contribution is very small, leaving financial performance dependent on licensing and milestone timing. This makes planning less predictable and increases the importance of successful commercialization or additional partnership income.
Regulatory Timing UncertaintyThe Zynquista regulatory timetable depends on adapting investigator-initiated study data for FDA submission, creating execution and timing uncertainty. Further delays could postpone a potential regulatory decision, commercialization plans, and any revenue or milestone benefits tied to approval.
Lexicon Pharmaceuticals News
LX31 FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was €0.95 and its highest was €1.45 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is €788.32M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 53 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -€0.061 earnings per share for the quarter, missing the consensus estimate of -€0.043 by -€0.017.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.05.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 444,955,930 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -€0.061 in its last earnings report, missing expectations of -€0.043. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:LX31
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€4.38 (334.04% Upside)
€4.38 (334.04% Upside)
Blogger Sentiment
Bullish
DE:LX31 Sentiment 67%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LX31 Company Deck
LX31 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful clinical and strategic progress — notably the over-enrollment of SONATA-HCM, approaching NDA resubmission for Zynquista supported by favorable STENO1 exposure and DKA data, international regulatory activity, and milestone-driven partnership progress (LX9851) — and the company strengthened liquidity with cash rising to $190.6M and a new Hercules loan facility. Counterbalancing these positives were a steep year-over-year revenue decline (driven by lack of prior-period licensing revenue), a return to a net loss of $31.8M, increased R&D spending, and some timing uncertainty due to reliance on an investigator-led study for NDA formatting and submission. Overall, the call presented strong operational and pipeline momentum alongside expected near-term financial volatility as the company invests in late-stage programs.View all DE:LX31 earnings summariesLX31 Stock 12 Month Forecast
Average Price Target
€4.38
▲(334.04% Upside)